US 11,730,709 B2
Compositions and methods for treating severe pain
Robin M. Bannister, Essex (GB); and John Brew, Hertfordshire (GB)
Assigned to Infirst Healthcare Limited, London (GB)
Filed by Infirst Healthcare Limited, London (GB)
Filed on Dec. 7, 2020, as Appl. No. 17/113,476.
Application 17/113,476 is a continuation of application No. 16/535,520, filed on Aug. 8, 2019, granted, now 10,667,941.
Application 16/535,520 is a continuation of application No. 15/684,197, filed on Aug. 23, 2017, granted, now 10,363,232.
Application 15/684,197 is a continuation of application No. 15/295,933, filed on Oct. 17, 2016, granted, now 9,795,577, issued on Oct. 24, 2017.
Application 15/295,933 is a continuation of application No. 14/975,599, filed on Dec. 18, 2015, granted, now 9,504,664, issued on Nov. 29, 2016.
Application 14/975,599 is a continuation of application No. 14/155,080, filed on Jan. 14, 2014, granted, now 9,265,742, issued on Feb. 23, 2016.
Application 14/155,080 is a continuation in part of application No. 13/365,824, filed on Feb. 3, 2012, granted, now 8,895,536, issued on Nov. 25, 2014.
Application 13/365,824 is a continuation in part of application No. PCT/GB2011/052115, filed on Oct. 31, 2011.
Application 14/155,080 is a continuation of application No. 13/365,828, filed on Feb. 3, 2012, granted, now 8,895,537.
Application 13/365,828 is a continuation in part of application No. PCT/GB2011/052115, filed on Oct. 31, 2011.
Claims priority of provisional application 61/752,309, filed on Feb. 4, 2013.
Claims priority of provisional application 61/752,356, filed on Jan. 14, 2013.
Claims priority of application No. 1018289 (GB), filed on Oct. 29, 2010; application No. 1101937 (GB), filed on Feb. 4, 2011; application No. 1113728 (GB), filed on Aug. 10, 2011; application No. 1113729 (GB), filed on Aug. 10, 2011; and application No. 1113730 (GB), filed on Aug. 10, 2011.
Prior Publication US 2021/0085505 A1, Mar. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/192 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 47/44 (2017.01); A61K 9/20 (2006.01); A61K 31/196 (2006.01); A61K 9/48 (2006.01); A61K 31/436 (2006.01); A61K 31/194 (2006.01); A61K 31/381 (2006.01); A61K 31/4035 (2006.01); A61K 31/421 (2006.01); A61K 31/423 (2006.01); A61F 5/02 (2006.01); A63B 23/02 (2006.01); A61K 31/60 (2006.01); A61K 9/00 (2006.01); A61K 31/19 (2006.01)
CPC A61K 31/192 (2013.01) [A61F 5/026 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2068 (2013.01); A61K 9/4875 (2013.01); A61K 31/194 (2013.01); A61K 31/196 (2013.01); A61K 31/381 (2013.01); A61K 31/4035 (2013.01); A61K 31/421 (2013.01); A61K 31/423 (2013.01); A61K 31/436 (2013.01); A61K 31/60 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/44 (2013.01); A63B 23/02 (2013.01); A61H 2201/0192 (2013.01); A61H 2201/1614 (2013.01); A61H 2201/1652 (2013.01); A61K 31/19 (2013.01)] 20 Claims
 
1. A pharmaceutical composition comprising:
a) about 10% to 30% of a propionic acid derivative NSAID by weight of the pharmaceutical composition, the NSAID including a free acid of a propionic acid derivative NSAID, a salt of a propionic acid derivative NSAID, a solvate of a propionic acid derivative NSAID, or a solvate of a salt of a propionic acid derivative NSAID;
b) about 5% to about 15% of a liquid polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition;
c) about 20% to about 50% of a hard fat by weight of the pharmaceutical composition, the hard fat comprising a mixture of triglycerides; and
d) about 10% to about 30% of a liquid fat by weight of the pharmaceutical composition, the liquid fat comprising a partially hydrolyzed glycerolipid,
wherein the pharmaceutical composition is formulated to have a melting point temperature in the range of about 25° C. or higher.